Email this page: News Release

Threshold Pharmaceuticals Presents Encouraging Data From Clinical Trials of TH-302 for Solid Tumors

To (email address):   Separate multiple addresses with commas. Maximum 200 characters.
Your name:
Your email address:   Copy yourself These email addresses will be used to email the page on your behalf and will not be used by Threshold Pharmaceuticals for any marketing purposes.
Add a comment:
Send:    Full page    Link to page
Type in number:
This helps Threshold Pharmaceuticals prevent automated submissions.